Vaccine Development and Manufacture –an Overvie · • CTD format: – Module 1: Administrative...
Transcript of Vaccine Development and Manufacture –an Overvie · • CTD format: – Module 1: Administrative...
Vaccine Development and Manufacture – an Overview
1
biotech.ca
Vaccine Industry Committee (VIC) members of BIOTECanada are vaccine manufacturers serving the Canadian market and early stage Canadian
companies developing advanced vaccines. The VIC receives funding from its member companies.
Disclosure Statement
biotech.ca
By the end of the seminar, participants will be able to:• Describe how vaccines are developed by industry and the process for submission for regulatory approval
• Describe vaccine manufacturing and quality control processes
Objectives
biotech.ca
Live viruses and bacteria (antigens) Registration and adherence to entire specific process, not just product composition.
Electron microscope image of vero cells (balls of sephadex) for Inactivated Polio Vaccine production (IPV)
Uniquely for Vaccines, THE PRODUCT IS THE PROCESS
biotech.ca
New Vaccine Development
Encouraging Vaccine Innovation: Promoting the Development of Vaccines that Minimize the Burden of Infectious Diseases in the 21st Century
biotech.ca6BIOTECanada’s Vaccine Industry Committee
Canadian Vaccine R&D and Manufacturing Sites
biotech.ca
• In order to register your product with Health Canada, you need appropriate clinical trials
• They should show your product is safe and effective
Clinical Trials
biotech.ca
• Health Canada approval of a Clinical Trial Application (CTA) is required to perform trials in humans
• The CTA is composed of three parts (modules):– Module 1 ‐ administrative and clinical information about the proposed trial
– Module 2 ‐ contains Quality (Chemistry and Manufacturing) information about the drug product(s) to be used in the proposed trial
– Module 3 ‐ contains additional supporting Quality information
• 30‐day review time
Clinical Trial Application
biotech.ca
• CTD format:– Module 1: Administrative and Product Information– Module 2: Common Technical Document (CTD) Summaries
– Module 3: Quality– Module 4: Nonclinical Study Reports– Module 5: Clinical Study Reports– Submissions are filed electronically (eCTD format)
• 300‐day review time
New Drug Submission
BIOTECanada’s Vaccine Industry Committee
biotech.ca10
VACCINES: A COMPLEX MANUFACTURING PROCESS
BIOTECanada’s Vaccine Industry Committee
A complex vaccine:
biotech.ca
Antigen Production
biotech.ca
Cell Culture
Monitored for:• Temperature• pH• Oxygen rate• Sterility• Homogeneity
biotech.ca
Isolation and Purification of the Antigens
Advances in Purification Technologies Accelerate Vaccine Development
biotech.ca
Formulation
biotech.ca15
Filling
• Filled into vials or syringes
• Vials can be liquid or freeze‐dried
biotech.ca
Inspection
biotech.ca17
Labelling and Packaging
BIOTECanada’s Vaccine Industry Committee
biotech.ca18
Revisiting the manufacturing overview
BIOTECanada’s Vaccine Industry Committee
A complex vaccine may :
biotech.ca
Testing – Throughout the process
Continuous testing
biotech.ca
On average, 4 years for worldwide approval of a post-approval change
biotech.ca
Vaccines – Complex in formulation, testing and maintenance
One vaccine =• Multiple biological antigens• Up to 50 manufacturing steps• 200+ analytical methods• 1200 + individual tests• Up to 3 years to manufacture and test• Up to 4 years to implement the change worldwide
biotech.ca
Questions?